Search | Clinical Trials Finder

Conditions: Wheezing, Asthma
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Destin, Florida • Miami, Florida + 11 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more

Conditions: Chronic Sinusitis, Nasal Polyps
Interventions: Biologic Agents; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Portland, Oregon • Charleston, South Carolina

Conditions: Asthma
Interventions: SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 18
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 935 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 92
States / cities: Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more

Conditions: Chronic Spontaneous Urticaria (CSU)
Interventions: Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 132
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 51
States / cities: Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more

Conditions: Eosinophilic Esophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 62
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 54 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more

Conditions: Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Dupilumab SAR231893, Placebo, non sedating H1-antihistamine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 16
States / cities: Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more

Conditions: Lichen Simplex Chronicus
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Anaheim, California • Fremont, California • Miami, Florida + 9 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Birmingham, Alabama • Miami, Florida • Cordele, Georgia + 7 more

Conditions: Asthma
Interventions: Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 50
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 42 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Atopic Dermatitis
Interventions: Abrocitinib 200 mg, Dupilumab 300 mg; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 49
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more

Conditions: Eosinophilic Oesophagitis
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more

Conditions: Dermatitis
Interventions: REGN668; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • Riverside, California • Miami, Florida + 7 more

Conditions: Atopic Dermatitis (AD)
Interventions: Dupilumab, Placebo, Background treatment; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Dallas, Texas

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peanut Allergy
Interventions: Dupilumab, Placebo matching dupilumab, AR101; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS); Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more

Conditions: Asthma
Interventions: Dupilumab Injectable Product; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Asthma
Interventions: dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more

Search by objective public record fields.

Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

Investigating Dupilumab's Effect in Asthma by Genotype

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Viral Infection in Asthma (VIA) Study

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma